Patents
Literature
3 results about "Immunoglobulin E" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunoglobulin E (IgE) is a type of antibody (or immunoglobulin (Ig) "isotype") that has only been found in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). IgE's main function is immunity to parasites such as helminths like Schistosoma mansoni, Trichinella spiralis, and Fasciola hepatica. IgE is utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum.
Anti-HER2 antibodies for use in the treatment of low-HER2-expressing tumors in the target population.
In one embodiment, the present invention relates to an anti-HER2 immunoglobulin E (IgE) antibody for use in the treatment of tumors with low HER2 expression in a subject. In another embodiment, the present invention provides an immunoglobulin that binds to HER2.
Owner:EPSILOGEN LTD
Use of lactobacillus casei gkc1 for the preparation of oral compositions for reducing the endotoxin content in serum
The present application relates to the use of Lactobacillus casei GKC1 for preparing an oral composition for reducing the endotoxin content in serum. After the administration of Lactobacillus casei GKC1 to a subject with respiratory allergy, the respiratory resistance of the subject is improved, and the content of immunoglobulin E specific to allergen and the content of endotoxin in the serum of the subject are reduced, so that Lactobacillus casei GKC1 can be used as an effective component of an oral composition for reducing the endotoxin content in serum.
Owner:GRAPE KING BIO LTD
composition
In one aspect, the present invention relates to immunoglobulin E (IgE) antibody for use in treating and / or delaying progression of cancer in a subject, wherein the antibody has a dissociation constant (Kd) for binding to a target antigen of 10 nM or less. In another aspect, immunoglobulins that bind to HER2 are provided.
Owner:EPSILOGEN LTD